ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements
Vaxfab Enterprises will hold a board meeting on 14 November 2026 to consider unaudited quarterly results. Trading window stays closed until 48 hours after results.
Vaxfab Enterprises appointed ASGM & Co. as forensic auditor for FY2023-FY2025 records. The probe follows management transition gaps and GST notices, with fees of ₹3 lakh.
Vaxfab Enterprises Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026. The filing provides current stake details.
Vaxfab Enterprises appointed Mrs. Dhruvi Patel as Company Secretary and Compliance Officer. This follows the resignation of Mrs. Neha Rishabh Bardia from the same position.
Vaxfab Enterprises Ltd held its Annual General Meeting on September 29, 2026. Shareholders approved financial statements, director reappointment, auditor appointment, and authorized capital increase.
The company filed the confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Vaxfab Enterprises approved raising up to ₹45 Crore through a rights issue of equity shares. A Rights Issue Committee was formed to manage the process.
Vaxfab Enterprises Ltd held its 43rd Annual General Meeting on September 29, 2026. The meeting covered routine business, director reappointment, and authorized share capital increase.
Vaxfab Enterprises Ltd has scheduled a board meeting for October 01, 2026, to consider a proposal for raising funds through the issuance of securities.
Vaxfab Enterprises Limited has scheduled its 43rd Annual General Meeting for September 29, 2026. The meeting will address financial adoption, director reappointment, and authorized capital increase.
Vaxfab Enterprises Ltd approved an increase in its authorized share capital from 3.5 Crore to 5 Crore equity/preference shares. The proposal awaits shareholder approval.
Vaxfab Enterprises' board approved increasing authorized capital from ₹35 Cr to ₹50 Cr and set the 43rd AGM for 29 September 2026.
Vaxfab Enterprises Limited allotted 8,26,761 equity shares upon conversion of warrants on a preferential basis. This issuance increases the company's paid-up equity share capital.
Vaxfab Enterprises Ltd reported revenue from operations of ₹0.4 Cr (-97.3% YoY) and a net loss of ₹5.8 Cr for Q1 FY27.
Vaxfab Enterprises has incorporated a new wholly owned subsidiary, Al Rafa Enterprise FZ-LLC, in the United Arab Emirates. The entity is yet to commence business operations.
Vaxfab Enterprises has scheduled a board meeting for August 14, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Vaxfab Enterprises disclosed shareholding patterns for the quarter ending June 30, 2026. This follows multiple preferential allotments of warrants and equity shares approved between January and May 2026.
Vaxfab Enterprises Ltd reports the Board's approval of audited standalone and consolidated financial results for FY 2025‑26. The outcome is filed as a revised board meeting notice.
Vaxfab Enterprises Ltd reported revenue from operations of ₹46 Cr (+90.1% YoY) and net profit of ₹2.1 Cr (+162.5% YoY) for Q4 FY26.
Vaxfab Enterprises Ltd reported revenue from operations of ₹8.8 Cr (-85.0% YoY) and net profit of ₹3 Cr (+328.6% YoY) for Q4 FY26.
Vaxfab Enterprises approved its audited FY26 financial results, reporting standalone total revenue of ₹99.60 Crore. The statutory auditor issued a disclaimer of opinion regarding record maintenance.
Vaxfab Enterprises Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with SEBI norms.
Vaxfab Enterprises scheduled a Board Meeting on May 30, 2026, to approve audited financial results. The trading window remains closed for designated persons until June 1.
Vaxfab Enterprises corrected a clerical error regarding the allotment of 14,81,068 equity shares. This issuance, valued at ₹3.11 Crore, follows a warrant conversion exercise.
Vaxfab Enterprises allotted 19,50,348 equity shares following warrant conversions at Rs. 21.02 each. This ₹4.1 Crore issuance increases the total paid-up capital to ₹25.47 Crore.
Vaxfab Enterprises Limited allotted 13,18,550 equity shares at ₹21.02 each following the conversion of warrants. This transaction, valued at approximately ₹2.77 Crore, increased the company's paid-up equity share capital to ₹23.52 Crore.
Vaxfab Enterprises Ltd clarified a typographical error regarding its March 17, 2026, warrant conversion outcome. The corrected allotment is 27,33,902 equity shares at Rs. 21.02 each, totaling approximately ₹5.75 Crore. All other terms and conditions of the allotment remain unchanged.
Vaxfab Enterprises Ltd reported its unaudited financial results for the quarter ended December 31, 2025. Consolidated total income stood at ₹12.29 Crore, with a net loss of ₹3.24 Crore. The statutory auditors issued a disclaimer of opinion due to missing historical records and lack of documentation regarding loans and asset impairments.